B. Riley Keeps Buy on 4D Molecular After EyePoint’s Phase 3 Miss
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.
/ 3 items
#FDMT↓
B. Riley Initiates Coverage on 4D Molecular with $37 Target — 267% Upside Potential
4D Molecular’s gene therapy could reduce eye injections for AMD patients. B. Riley sees major upside if Phase 3 results succeed. 4D-150 gene therapy fully funded to H2 2028.
4DMT Partners with Otsuka for Revolutionary Eye Disease Treatment in Asia-Pacific
4D Molecular Therapeutics secures $85M upfront deal with Otsuka Pharmaceutical to bring 4D-150, a potential one-time eye injection treatment, to Asia-Pacific markets.